What are the indications for the tablet containing Cissus quadrangularis 500 mg, Moringa oleifera 100 mg, Chiroy 50 mg, Ascorbic acid 8 mg, Copper 0.4 mg, Chromium 10 µg, Molybdenum 9 µg, Selenium 5.2 µg, Boron 150 µg and Vitamin D3 25 µg?

Indications for This Multi-Ingredient Bone Health Supplement

This formulation is primarily indicated for bone health support, specifically for fracture healing acceleration, osteopenia/early bone loss prevention, and as adjunctive therapy in metabolic bone disorders, though it contains suboptimal doses of several key components compared to evidence-based recommendations.

Primary Indications Based on Component Evidence

Bone Health and Fracture Healing

The combination targets bone metabolism through multiple mechanisms:

• Cissus quadrangularis (500 mg) serves as the primary active ingredient with documented effects on bone healing. Clinical evidence shows CQ accelerates fracture healing, reduces bone pain, and increases functional recovery in maxillofacial and mandibular fractures 1, 2. The 500 mg dose aligns with research demonstrating benefits for bone fractures and stabilization of bone turnover markers in postmenopausal osteopenia over 24 weeks 2, 3.

• Vitamin D3 (25 mcg/1000 IU) supports calcium absorption and bone mineralization. However, this dose is critically inadequate for most clinical scenarios. Guidelines recommend 800-1000 IU daily for adults over 50 for basic bone health 4, but many patients require substantially more to achieve target serum 25(OH)D levels ≥30 ng/mL 4. For vitamin D deficiency (levels <30 ng/mL), standard repletion requires 50,000 IU weekly for 8 weeks 4.

Metabolic Support and Weight Management

• Cissus quadrangularis in combination formulations has shown efficacy for weight reduction and metabolic syndrome parameters. Studies demonstrate significant reductions in body weight (-5.19 kg), LDL cholesterol (-14.43 mg/dL), triglycerides (-37.50 mg/dL), total cholesterol (-50.50 mg/dL), and fasting blood glucose (-10.39 mg/dL) compared to placebo 2, 5.

• Moringa oleifera (100 mg) provides nutritional support with essential amino acids, minerals, vitamins, and phytochemicals that may address nutritional deficiencies and support metabolic health 6, 7.

Trace Mineral Supplementation

The micronutrients (copper 0.4 mg, chromium 10 mcg, molybdenum 9 mcg, selenium 5.2 mcg, boron 150 mcg) provide trace elements involved in bone metabolism and general health maintenance. However, these doses are minimal and unlikely to correct deficiencies 8.

Critical Dosing Concerns

The vitamin D3 content (1000 IU) is insufficient for therapeutic bone protection in most clinical scenarios. Standard recommendations call for:

• 800-1000 IU daily for basic maintenance in adults >50 4
• 1000-2000 IU daily for most patients requiring supplementation 9
• Much higher doses (50,000 IU weekly) for documented deficiency 4

The ascorbic acid dose (8 mg) is grossly inadequate, representing only 9-11% of the RDA (75-90 mg/day for adults) 8, 10.

Appropriate Clinical Use

This formulation is best suited for:

1. Adjunctive support during fracture healing - particularly maxillofacial or long bone fractures where CQ has demonstrated benefit
2. Early osteopenia management - as part of a comprehensive approach including adequate calcium intake (1200 mg/day total) 4
3. Metabolic syndrome with overweight/obesity - when combined with caloric restriction
4. Bone health maintenance during antiresorptive drug holidays - temporary support during bisphosphonate suspension 1

This formulation should NOT be used as:

• Sole therapy for vitamin D deficiency (dose too low)
• Primary treatment for established osteoporosis (requires bisphosphonates or other FDA-approved agents 4)
• Replacement for adequate calcium supplementation (contains no calcium)

Important Caveats

• Lack of standardization: CQ preparations vary widely in bioactive content; this formulation's specific CQ extract characteristics are unknown 1, 7
• Limited long-term data: Most CQ studies are short-term (8-24 weeks) with small sample sizes 2, 3
• Combination effects unclear: The specific synergy of these ingredients at these doses has not been studied
• Vitamin D monitoring essential: Serum 25(OH)D levels should be checked; most patients will require additional vitamin D supplementation beyond this formulation 4

Patients with established osteoporosis, significant vitamin D deficiency, or high fracture risk require evidence-based pharmacotherapy (bisphosphonates, denosumab, etc.) rather than relying on this supplement alone 4.